Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 10/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.60 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21425202 | 0.89 | BCL9 (0.56) | BCL9CTNNB1PDE4BALDH1A1LMNA | |
| SCHEMBL15649592 | 0.88 | PDE4B (0.54) | BCL9CTNNB1PROKR1PDE4BALDH1A1 | |
| SCHEMBL18618449 | 0.87 | MEN1 (0.56) | DRD2PDE4BALDH1A1MEN1KMT2A | |
| SCHEMBL4035035 | 0.87 | BCL9 (0.72) | BCL9CTNNB1 | |
| SCHEMBL4031537 | 0.86 | SIGMAR1 (0.54) | BCL9CTNNB1DRD2PDE4BUSP30 | |
| SCHEMBL14855709 | 0.85 | DRD2 (0.53) | BCL9CTNNB1DRD2PDE4BUSP30 | |
| SCHEMBL1439746 | 0.85 | PDE4B (0.51) | BCL9CTNNB1PDE4BUSP30 | |
| SCHEMBL31233097 | 0.85 | PDE4B (0.60) | BCL9CTNNB1PROKR1DRD2PDE4B | |
| SCHEMBL21359167 | 0.84 | PROKR1 (0.62) | BCL9CTNNB1PROKR1DRD2MYC | |
| SCHEMBL6359096 | 0.84 | ALDH1A1 (0.56) | PDE4BALDH1A1LMNAHPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| CN-112262129-A | Triazacyclododecane sulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3765447-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | BCL9 626/4885CTNNB1 4269/4885PROKR1 579/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | BCL9 787/4885CTNNB1 4309/4885PROKR1 600/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | BCL9 541/4885CTNNB1 2293/4885PROKR1 1113/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | BCL9 707/4885CTNNB1 4365/4885PROKR1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.